z-logo
Premium
A Versatile and Clearable Nanocarbon Theranostic Based on Carbon Dots and Gadolinium Metallofullerene Nanocrystals
Author(s) -
Guan Mirong,
Li Jie,
Jia Qingyan,
Ge Jiechao,
Chen Daiqin,
Zhou Yue,
Wang Pengfei,
Zou Toujun,
Zhen Mingming,
Wang Chunru,
Shu Chunying
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201600402
Subject(s) - metallofullerene , materials science , nanotechnology , carbon fibers , carbon nanotube , nanoparticle , nanocages , gadolinium , photon upconversion , nanocomposite , nanocrystal , in vivo , quantum dot , graphene , fullerene , chemistry , luminescence , optoelectronics , composite number , metal , composite material , biochemistry , catalysis , organic chemistry , metallurgy , microbiology and biotechnology , biology
Nanocarbons such as carbon nanotubes, graphene derivatives, and carbon nanohorns have illustrated their potential uses as cancer theranostics owing to their intrinsic fluorescence or NIR absorbance as well as superior cargo loading capacity. However, some problems still need to be addressed, such as the fates and long‐term toxicology of different nanocarbons in vivo and the improvement of their performance in various biomedical imaging‐guided cancer therapy systems. Herein, a versatile and clearable nanocarbon theranostic based on carbon dots (CDs) and gadolinium metallofullerene nanocrystals (GFNCs) is first developed, in which GFNCs enhance the tumor accumulation of CDs, and CDs enhance the relaxivity of GFNCs, leading to an efficient multimodal imaging‐guided photodynamic therapy in vivo without obvious long‐term toxicity. Furthermore, biochemical analysis reveals that the novel nanotheranostic can harmlessly eliminate from the body in a reasonable period of time after exerting diagnostic and therapeutic function.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here